Shahid Qamar, MD
Advanced Heart Failure and Transplant Cardiology · Orlando, FLNPI 1912184730
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $5,450 of the $8,893 with a category attached, or 61.3%. AstraZeneca accounts for 64.7% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2020 at $3,486 and has fallen 86.9% since, to $456 in 2025.
Across 119 payments — averaging $74.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$6K
- Abbott$835
- Actelion Pharmaceuticals US, Inc.$424
- United Therapeutics Corporation$297
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$297
- Impulse Dynamics (USA) Inc.$286
- plus $1K from 15 others
Across 9 payments — averaging $3214.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$14K
- Alnylam Pharmaceuticals Inc.$11K
- Analog Devices Inc.$4K
What the payments were for
- Speaking & faculty fees$5,45061%
- Food & beverage$3,25337%
- Education$1912%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 15 | $5,753 |
| Abbott | 10 | $835 |
| Actelion Pharmaceuticals US, Inc. | 16 | $424 |
| United Therapeutics Corporation | 7 | $297 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 21 | $297 |
| Impulse Dynamics (USA) Inc. | 3 | $286 |
| Abiomed | 3 | $238 |
| Novartis | 12 | $163 |
| Medtronic | 4 | $83 |
| Cvrx, Inc. | 2 | $80 |
| Pfizer | 5 | $79 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $62 |
| Alnylam Pharmaceuticals Inc. | 4 | $58 |
| Boston Scientific | 2 | $44 |
| Scpharmaceuticals Inc. | 2 | $37 |
| Novo Nordisk | 2 | $36 |
| Boehringer Ingelheim | 2 | $35 |
| Merck | 2 | $35 |
| Amgen | 1 | $19 |
| Livanova USA, Inc. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$5,576
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$505
- OPTIMIZER$410
- ORENITRAM$122
- MitraClip System$120
- Impella$114
- HeartMate$112
How this compares
$8,893 in reported general payments places this provider in the 60th percentile of 48 advanced heart failure and transplant cardiology providers in Florida.
See all advanced heart failure and transplant cardiology providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 293 | $6,698,954 |
| EntrestoSacubitril/Valsartan | 278 | $314,950 |
| EliquisApixaban | 252 | $284,798 |
| JardianceEmpagliflozin | 233 | $264,243 |
| FarxigaDapagliflozin Propanediol | 103 | $106,281 |
| XareltoRivaroxaban | 31 | $38,779 |
| Milrinone Lactate | 23 | $6,927 |
| Torsemide | 180 | $4,749 |
| Metoprolol Succinate | 243 | $3,380 |
| Midodrine Hcl | 39 | $2,722 |
| Bumetanide | 73 | $2,668 |
| Ranolazine ErRanolazine | 20 | $2,086 |
| Enoxaparin Sodium | 16 | $1,729 |
| Atorvastatin Calcium | 189 | $1,610 |
| Spironolactone | 232 | $1,606 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $79 | $6,983,752545 claims |
| NovartisEntresto | $163 | $314,950278 claims |
| Boehringer IngelheimJardiance | $35 | $264,243233 claims |
| AstraZenecaFarxiga | $5,753 | $106,281103 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 48 advanced heart failure and transplant cardiology providers in Florida.
Other advanced heart failure and transplant cardiology in Orlando
- Naveen BellamOrlando$414K
- Stacy MandrasOrlando$100K
- Pujan PatelOrlando$66K
- Andrija VidicOrlando$18K
- Jacqueline DoweOrlando$7K
- Sushma KoneruOrlando$7K
- Mauricio VelezOrlando$6K
- Akanksha AgrawalOrlando$5K
- Krithika KrishnaraoOrlando$4K
- Maria DemoriOrlando$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.